A soluble form of the interleukin-1 receptor produced by a human B cell line  by Symons, J.A. & Duff, G.W.
Volume 272, number 1,2, 133-136 FEBS 08975 October 1990 
A soluble form of the interleukin-l receptor produced by a 
human B cell line 
J.A. Symons and G.W. Duff 
University of ~~inb~rg~ Deportment o~~edici~, ~o~e~~lur Imm~oiog~ Group, northern General Hos~~t~, Edinburgh, 
EH5 2DQ. UK 
Received 13 August 1990 
A soluble protein that binds specifically to interleukin-1 (IL-l)@ was released from a B cell line (Raji). The covalently cross-linked binding protein/ 
PzsI]IL-l/l migrated at 40 kDa by SDS-PAGE. The IL-1 receptor (IL-IR) on Raji cells had the same ligand specificity. Stim~ation of Raji with 
dexamethasone increased surface expression of the IL-1R and the rate of release of soluble binding protein. A serine protease inhibitor prevented 
release of the binding protein and increased IL-1R expression on the cells. These results suggest hat the soluble IL-l/J binding protein is a proteolyti- 
tally cleaved form of the novel B cell IL-1R. 
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1. INTRODUCTION 
Interleukin 1 (IL-lb andp are polypeptide cytokines 
with proinflammatory and immune-potentiating ef- 
fects in vivo and in vitro [ 11. IL-l is produced by a varie- 
ty of cells and acts via specific high affinity cell surface 
receptors. At least two IL-l receptor (IL-1R) proteins 
exist [2,3]. An 80 kDa protein cloned from murine [4] 
and human [S] T cells that is also present on fibroblasts 
binds both IL-la and IL-lb with equal affi~ty 161. The 
murine and human receptors are 69% homologous at 
the amino acid level and are members of the im- 
munoglobulin gene superfamily [5]. 
A lower molecular mass IL-l R protein (60-70 kDa) is 
expressed on B cells and macrophages 171. Like the 80 
kDa receptor the low molecular mass receptor is heavily 
glycosylated containing approximately 13 kDa of N- 
linked carbohydrate [8]. Interestingly, some B cells ex- 
pressing the 60 kDa receptor appear to bind IL-la and 
IL-l@ with different affinities [9,10]. Many cytokine 
receptor proteins are known to exist in soluble form 
either by alternative splicing of mRNA to give a 
secreted isoform e.g. IL4R [11] or by proteolytic 
cleavage of the transmembrane molecule at the cell sur- 
face e.g, IL-2R (~55) [12]. Other cytokine receptors 
shown to exist in soluble form include those for IL-6,~- 
IFN, TNF, IL-7, EGF and M-CSF. 
We have recently described the presence of a soluble 
binding protein specific for IL-l@ in normal human 
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plasma [ 131, serum, synovial inflammatory exudate and 
activated mononuclear cell supernatants [14]. In this 
paper we describe the presence of this protein in the 
supernatant of a human B cell Burkitt lymphoma cell 
line (Raji), a cell that expresses the 60 kDa receptor pro- 
tein and present evidence that it is a soluble form of this 
receptor. There have been o previous reports of a 
naturally-occurring soluble IL-1 receptor. 
2. MATERIALS AND METHODS 
2.1. Reagents and cell culture 
Radioiodinated human recombinant (hr) IL-lcr and hr IL-I@ were 
obtained from DuPont (NEN Products, Herts, UK; spec. act. 85.9 
pCi/pg and 158 &i/,ug respectively). Human recombinant (hr) 
cytokines were a gift from Glaxo Institute for Molecular Biology, 
Geneva, Switzerland. All hr peptides were regularly assessed for 
bioactivity. Disuccinimide suberate (DSS) was obtained from Pierce 
and Warriner Ltd (Chester, UK), and all other chemicals from Sigma 
(Dorset, UK). The human Burkittlymphoma B cell line, Raji and the 
murine thymoma EL-4 NOB.1 T cell line were obtained from the 
European Cell Culture Collection (Porton, Wilts, UK). Cells were 
maintained at 37°C in RPM1 1640 as described previously 113,141. 
Raji cells were washed twice in fresh serum-fre medium and cultured 
at 2.5 x 106/ml in 1 ml ahquots for up to 72 h. Cell-free supernatants 
obtained by centrifugation at 900 xg for 5 min were stored at - 20°C 
until used. The remaining cells were washed and resuspended in bin- 
ding medium (RPM1 1640 containing 1% (w/v) bovine serum 
atbumin, 0.1% (w/v) sodium azide and 20 mM HEPES, pH 7.2) to 
assess surface IL-1 receptor expression. 
2.2. Cell surface affinity crosslinking 
Raji and EL-4 NOB.1 cells (1 x 10’) were covalently crosslinked to 
[‘251]IL-l as previously described [14]. After crosslinking the cells 
were solubilised in PBS containing SDS (1% w/v) and protease ln- 
hibitors and analysed in lOolo SDS-PAGE gels [14]. 
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2.3. Soluble covalent cross-linking and SDS-PAGE analysis 
Analysis of soluble IL-l binding proteins in Raji cell culture super- 
natants (50 p)l was performed as previously described in detail 
[13,14]. 
2.4. Soluble and cell surface [‘z51]IL-l bindings assay 
Soluble binding assays on Raji supernatants were performed as 
previously described [14]. Supernatants (100 pl) were incubated with 
5 ng/ml [‘251]IL-lfl in a final volume of 0.2 ml for 2 h at 20°C. All 
experiments were performed in duplicate and results were expressed 
as specific binding activity after subtraction of non-specific binding. 
Cell surface binding assays were performed according to Dower et 
al. [lS]. Cells (1 x 106) were incubated with 5 ng/ml [iz51]IL-lain 150 
pl binding medium or binding medium containing lOO-fold excess 
unlabelled IL-la for 3h at 4°C with constant agitation. The cells were 
then washed twice in ice-cold protein-free buffer and resuspended in 
100 pl of the same buffer. Bound and free [lzsI]IL-lfi were separated 
by layering duplicate 50~1 aliquots on to 300~1 of a phthalate oil mix- 
ture (1.5 parts dibutyl phthalate (Sigma) and 1 part dioctyl phthalate 
(Aldrich Chemical Co.)). Tubes were centrifuged for 90 s at 10000 x g 
the tips excised and counted in a gamma counter. 
3. RESULTS 
3.1. Covalent crosslinking to cell surface binding 
proteins 
Iodinated IL-lb was covalently crosslinked to Raji 
cells and the detergent extracts analysed by SDS-PAGE 
(Fig. 1A). One species of binding protein was observed 
that, when cross-linked to IL-l, migrated at approx- 
imately 82 kDa, representing acell surface protein of 65 
kDa. This band was detectable in the presence of excess 
cold hr IL-la but not in the presence of excess hr IL-l/3. 
In contrast, IL-lcu crosslinked to EL-4 NOB.1 T cells 
revealed a 97 kDa band representing an 80 kDa receptor 
protein. Binding of [‘251]IL-la to this protein was in- 
hibited both by cold IL-la and IL-l/3 (Fig. 1B). 
3.2. Covalent crosslinking to soluble binding proteins 
Soluble IL-1 binding proteins in Raji cell super- 
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natants were identified by crosslinking to iodinated 
IL-l. When IL-la cross-linked to Raji supernatant was 
analysed by SDS-PAGE, no specific binding was 
observed (Fig. 2A). In contrast, when [‘251]IL-1fl was 
covalently crosslinked by Raji supernatant a major 
[1251]IL-l&protein complex migrated as a broad band 
at approximately 60 kDa (Fig. 2B). This binding was 
displaceable by lOO-fold excess cold IL-lp but not by 
other cold cytokines. EL-4 NOB.1 cells did not release 
any detectable specific IL-l binding proteins (data not 
shown). 
3.3. Time course of IL-l receptor expression and 
release 
Raji cells were incubated with either media or 
dexamethasone-acetate (500 nM) for up to 72 h. At each 
time point supernatants and cells were assessed for 
specific IL-l& binding. Raji cell surface IL-1R expres- 
sion did not change during the 72 h culture period when 
the cells were incubated in medium alone. However, 
there was an accumulation of soluble binding protein 
over the same culture period (Fig. 3). In contrast, when 
Raji cells were incubated with 500 nM dexamethasone, 
cell surface receptor expression was significantly in- 
creased over cells incubated in media alone at 48 and 72 
h of culture. Concurrently soluble binding levels were 
also elevated at these time periods compared to the con- 
trol culture supernatants (Fig. 3). 
3.4. Effect of metabolic and protease inhibitors on 
Raji IL-1R 
To elucidate the mechanism of Raji IL-1R release, 
Raji cells were incubated for 48 h with or without a 
range of metabolic or protease inhibitors. Subsequently 
both cell surface and supernatant receptor levels were 
assessed by IL-lb binding (Fig. 4). Cyclohexamide (1 
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Fig. 1. Affinity cross-linking of [‘*‘I]IL-18 to Raji cells (A) and [‘251]IL-la to EL-4 NOB.1 cells (B). In each case, Lane 1 with no competing agent. 
Lane 2 with excess IL-la. Lane 3 with excess IL-l,&. Protein markers are in kDa. 
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Fig. 2. Affinity cross-linking of [‘251]IL-l to Raji supernatant proteins. (A) With [lZSI]IL-la, (B) with [‘251]IL-lfi. In each case lane 1 with no com- 
peting agent; lane 2 with excess IL-la. Lane 3 with excess IL-lb, lane 4 with excess TNF-cY, lane 5 with excess TNF,B, lane 6 with excess IL-6. 
pug/ml) and actinomycin D (5 pg/ml) reduced cell sur- 
face IL-1R expression and reduced soluble binding to 
undetectable levels. Aprotinin (50/1g/ml), a serine pro- 
tease inhibitor, doubled the level of cell surface IL-1R 
expression and at the same time reduced soluble binding 
to undetectable levels. In contrast chymostatin (50 
pg/ml) had no significant effects on cell surface or solu- 
ble binding levels. Chloroquine (2OOpM), an agent that 
blocks receptor internalisation and lysosomal degrada- 
tion increased Raji cell surface IL-1R expression 8-fold 
and soluble binding 2-fold. Monensin (2pM) had no ef- 
fect on cell surface IL-1R expression but decreased 
soluble binding protein levels by 60%. None of the 
treatments significantly reduced cell viability. 
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Fig. 3. Time course of Raji cell and supernatant IL-1R accumulation 
in response to dexamethasone (Dex). Raji cell surface IL-1R 
(M), Raji cell surface IL-1R plus Dex (O---O), Raji supernatant 
IL-1R (ti), Raji supernatant plus Dex (A---A). Data shown is 
representative of 3 experiments. 
4. DISCUSSION 
Analysis of Raji supernatants cross-linked with 
iodinated IL-l revealed a protein that bound to IL-l,& 
but not IL-la. We have previously described a protein 
with the same properties in normal human plasma, 
serum, synovial exudate and supernatants from ac- 
tivated blood mononuclear cells [ 13,141. The Raji cell 
surface IL-1R had an identical specificity as has also 
been reported by others [23]. Stimulation of B cells with 
glucocorticoids increases cell surface expression of 
II-IR [ 10,161. We confirmed this and also found that 
stimulation of Raji cells with dexamethasone increased 
the levels of soluble IL-la binding proteins. 
Fig. 4. Effect of metabolic and protease inhibitors on Raji IL-1R. 
Shaded bars represent cell surface levels, open bars supernatant 
levels. Binding shown represents specific binding. Bars represent 
mean f SEM (n = 3). 
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One mechanism of cell surface receptor release is by 
proteolytic cleavage so we tested protease inhibitors on 
the release of the IL-lb binding protein. Aprotinin, a 
serine protease inhibitor increased cell surface IL-1R 
expression 2-fold while soluble IL-l,& binding became 
undetectable. The lysomotropic agent chloroquine 
caused an 8-fold increase in cell surface IL-1R expres- 
sion and a significant increase in soluble binding levels. 
The data suggest he cell surface IL-l receptor is recycl- 
ed and a soluble binding protein is created by the action 
of a serine protease at the cell surface. Further, the rate 
of release is related to the level of cell surface IL-1R ex- 
pression. 
It is now recognised that the IL-1R on T cells and 
fibroblasts is a separate gene product to that found on 
B cells [2,3], although cells expressing both have been 
described [9,17,23]. Recent studies have indicated that 
the two receptors may bind IL-la and $3 with different 
affinities [9,10,23]. Interestingly, there are many 
reports of biological systems where IL-l@ is more po- 
tent than 11-1~~. In the brain II-lfl is more effective in in- 
ducing fever [ 181 and ovarian granulosa cell differentia- 
tion is inhibited to a greater extent by IL-l,& than IL-la 
[19]. In vivo IL-lcu and IL-lfl produce similar 
pyrogenicity and acute phase response, but only IL-lb 
shows immunostimulatory activity [20]. Pancreatic fl- 
islet cells express receptors specific for IL-lfl [21] and 
islet cell cytotoxicity is only mediated by IL-lfl [22]. 
Given that the soluble IL-1R appears to have a ligand 
affinity similar to the cell surface receptor [14] it may 
function as a specific inhibitor of IL-lfl. There are no 
previous reports of a naturally-occurring soluble IL-l 
receptor and the molecular structure of the 60 kDa B 
cell IL-1 receptor from which we believe the soluble 
binding molecule is derived has not yet been reported. 
The production of soluble binding protein by a B cell 
line should provide adequate material for purification 
and characterisation of this apparently novel IL-l 
receptor. 
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